These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10226930)

  • 21. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis.
    Delatycki MB; Allen KJ; Nisselle AE; Collins V; Metcalfe S; du Sart D; Halliday J; Aitken MA; Macciocca I; Hill V; Wakefield A; Ritchie A; Gason AA; Nicoll AJ; Powell LW; Williamson R
    Lancet; 2005 Jul 23-29; 366(9482):314-6. PubMed ID: 16039334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asymptomatic individuals at genetic risk of haemochromatosis take appropriate steps to prevent disease related to iron overload.
    Allen KJ; Nisselle AE; Collins VR; Williamson R; Delatycki MB
    Liver Int; 2008 Mar; 28(3):363-9. PubMed ID: 18290779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is DNA testing for hemochromatosis diagnosis reliable?
    Adams PC
    Expert Rev Mol Diagn; 2017 Mar; 17(3):203-204. PubMed ID: 28092202
    [No Abstract]   [Full Text] [Related]  

  • 25. Hereditary haemochromatosis - diagnosis and management.
    Allen K
    Aust Fam Physician; 2010 Dec; 39(12):938-41. PubMed ID: 21301675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population screening for haemochromatosis: expectations based on a study of relatives of symptomatic probands.
    Bradley LA; Haddow JE; Palomaki GE
    J Med Screen; 1996; 3(4):171-7. PubMed ID: 9041480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-focused outcomes following detection in a hospital-based screening programme for C282Y haemochromatosis.
    McCullen MA; Fletcher LM; Dimeski G; Pink A; Powell LW; Crawford DH; Hickman PE
    Intern Med J; 2008 Aug; 38(8):651-6. PubMed ID: 18284459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Frequency of HFE gene mutations and genotype-phenotype correlations in patients with hereditary hemochromatosis in Switzerland].
    Himmelmann A; Bortoluzzi L; Jansen S; Fehr J
    Schweiz Med Wochenschr; 2000 Aug; 130(31-32):1112-9. PubMed ID: 11008304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ethical implications and practical considerations of ethnically targeted screening for genetic disorders: the case of hemoglobinopathy screening.
    Hinton CF; Grant AM; Grosse SD
    Ethn Health; 2011; 16(4-5):377-88. PubMed ID: 21797724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanding the newborn screen: terrific or troubling?
    Kunk RM
    MCN Am J Matern Child Nurs; 1998; 23(5):266-71. PubMed ID: 9747090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Best practice guidelines for the molecular genetic diagnosis of Type 1 (HFE-related) hereditary haemochromatosis.
    King C; Barton DE
    BMC Med Genet; 2006 Nov; 7():81. PubMed ID: 17134494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues.
    Bailey DB; Skinner D; Davis AM; Whitmarsh I; Powell C
    Pediatrics; 2008 Mar; 121(3):e693-704. PubMed ID: 18310190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haemochromatosis.
    Adams PC; Barton JC
    Lancet; 2007 Dec; 370(9602):1855-60. PubMed ID: 18061062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for cystic fibrosis.
    Dodge JA; Ryley HC
    Arch Dis Child; 1982 Oct; 57(10):774-80. PubMed ID: 7138066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs associated with hereditary haemochromatosis in Australia: a cost-of-illness study.
    de Graaff B; Neil A; Sanderson K; Yee KC; Palmer AJ
    Aust Health Rev; 2017 Jul; 41(3):254-267. PubMed ID: 27444148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [High-dose immunoglobulin during pregnancy for two patients with risk of recurrent neonatal haemochromatosis].
    Carrabin N; Cordier MP; Gaucherand P
    J Gynecol Obstet Biol Reprod (Paris); 2007 Jun; 36(4):409-12. PubMed ID: 17446006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis.
    Hickman PE; Hourigan LF; Powell LW; Cordingley F; Dimeski G; Ormiston B; Shaw J; Ferguson W; Johnson M; Ascough J; McDonell K; Pink A; Crawford DH
    Gut; 2000 Mar; 46(3):405-9. PubMed ID: 10673305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Issues in newborn screening.
    Saxena A
    Genet Test; 2003; 7(2):131-4. PubMed ID: 12885334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Australia: public health genomics.
    Metcalfe SA; Bittles AH; O'Leary P; Emery J
    Public Health Genomics; 2009; 12(2):121-8. PubMed ID: 19039256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetes and haemochromatosis: current concepts, management and prevention.
    Yaouanq JM
    Diabete Metab; 1995 Dec; 21(5):319-29. PubMed ID: 8586148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.